Mufg Securities Americas Inc. Takes Position in Amgen Inc. (NASDAQ:AMGN)

Mufg Securities Americas Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 7,936 shares of the medical research company's stock, valued at approximately $2,068,000.

Other large investors also recently modified their holdings of the company. Centricity Wealth Management LLC bought a new stake in Amgen during the 4th quarter worth approximately $25,000. Ritter Daniher Financial Advisory LLC DE grew its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new stake in Amgen during the 4th quarter worth approximately $34,000. Atala Financial Inc bought a new stake in Amgen during the 4th quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new stake in Amgen during the 4th quarter worth approximately $36,000. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AMGN shares. Bank of America increased their price target on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Cantor Fitzgerald initiated coverage on Amgen in a report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective on the stock. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Erste Group Bank downgraded Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Finally, Piper Sandler reduced their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a report on Friday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $310.18.

Amgen Trading Up 0.3%

Amgen stock traded up $0.72 during mid-day trading on Friday, hitting $272.41. 2,588,369 shares of the company's stock were exchanged, compared to its average volume of 2,789,152. The firm has a market capitalization of $146.48 billion, a P/E ratio of 36.08, a PEG ratio of 2.63 and a beta of 0.51. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company's 50 day simple moving average is $291.00 and its 200-day simple moving average is $288.28.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.96 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 86.86%.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.76% of the company's stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.